| **Author year  Country *Quality*** | **Treatment Regimen (1x/day unless otherwise noted)** | **Treatment Duration and Assessments** | **Overall SVR Results** | **Genotype SVR Results** | **Other Subgroup SVR Results** |
| --- | --- | --- | --- | --- | --- |
| Abergel 2016a142 France *Fair* | Ledipasvir 90 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks Timing of assessment: 12 weeks post-treatment | SVR: 96% (21/22) | Genotype 4: 96% (21/22) | NR |
| Abergel 2016b141 France *Good* | Ledipasvir 90 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks Timing of assessment: 12 weeks post-treatment | SVR: 95% (20/21) | Genotype 5: 95% (20/21) | NR |
| Afdhal 2014185  ION-1  U.S. and Europe  *Fair* | A. Ledipasvir 90 mg + sofosbuvir 400 mg  B. Ledipasvir 90 mg + sofosbuvir 400 mg + ribavirin | Treatment duration: 12 to 24 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B  12-week intervention group  SVR: 99% (211/214) vs. 97% (211/217)  24-week intervention group  SVR: 98% (212/217) vs. 99% (215/217) | A vs. B  SVR, 12-week intervention group\*  Genotype 1a: 99% (141/142) vs. 100% (143/143)  Genotype 1b: 100% (66/66) vs. 100% (67/67)  Other: 100% (4/4) vs. 100% (1/1)  SVR, 24-week intervention group\*  Genotype 1a: 100% (143/143) vs. 100% (141/141)  Genotype 1b: 97% (66/68) vs. 100% (71/71)  Other: 100% (3/3) vs. 100% (3/3) | A vs. B  SVR, 12-week intervention group\*  <65 years: 99% (196/197) vs. 100% (189/189)  ≥65 years: 100% (15/15) vs. 100% (22/22)  Male: 99% (125/126) vs. 100% (124/124)  Female: 100% (86/86) vs. 100% (87/87)  Black: 100% (24/24) vs. 100% (26/26)  Non-Black: 99.5% (187.188) vs. 100% (184/184)  Hispanic: 100% (26/26) vs. 100% (19/19)  Non-Hispanic: 99.5% (184/185) vs. 100% (192/192)  No cirrhosis: 100% (179/179) vs. 100% (178/178)  Cirrhosis: 97% (32/33) vs. 100% (33/33)  SVR, 24-week intervention group\*  <65 years: 99.5% (191/192) vs. 100% (202/202)  ≥65 years: 96% (21/22) vs. 100% (13/13)  Male: 99% (136/138) vs. 100% (118/118)  Female: 100% (76/76) vs. 100% (97/97)  Black: 94% (29/31) vs. 100% (26/26)  Non-Black: 100% (183/183) vs. 100% (188/188)  Hispanic: 100% (29/29) vs. 100% (26/26)  Non-Hispanic: 100% (183/183) vs. 100% (188/188)  No cirrhosis: 99.5% (181/182) vs. 100% (179/179)  Cirrhosis: 97% (31/32) vs. 100% (36/36) |
| Ahmed 2018195 Egypt  *Fair* | Ledipasvir 90 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 99% (99/100) | Genotype 4: 99% (99/100) | NR |
| Andreone 2014186 PEARL-II Austria, Belgium, Italy, The Netherlands, Portugal, Puerto Rico, Sweden, Switzerland, U.S. *Fair* | A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day  B. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day + ribavirin | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B  SVR: 100% (91/91) vs. 97% (85/88) | A vs. B  Genotype 1b: 100% (91/91) vs. 97% (85/88) | A vs. B  Male: 100% (54/54) vs. 95% (41/43)  Female: 100% (37/37) vs. 98% (44/45)  Black: 100% (5/5) vs. 100% (3/3)  Other: 100% (86/86) vs. 97% (82/85) |
| Asselah 2018196  SURVEYOR II Part 4, Multinational (Asia, Europe, U.S. [specific countries NR])  *Fair* | Glecaprevir 300 mg + pibrentasvir 120 mg | Treatment duration: 8 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 97% (196/203) | Genotype 2: 98% (142/145)  Genotype 4: 93% (43/46)  Genotype 5: 100% (2/2)  Genotype 6: 90% (9/10) | NR |
| Asselah 2019143 ENDURANCE-5 Multinational (Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam, U.S.)  *Fair* | Glecaprevir 300 mg + pibrentasvir 120 mg | Treatment duration: 8 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 96% (22/23) | Genotype 5: 96% (22/23) | NR (reported for combined genotypes only) |
| Asselah 2019143 ENDURANCE-6  (same publication as ENDURANCE-5)  *Fair* | See Asselah 2019  ENDURANCE-5 | See Asselah 2019  ENDURANCE-5 | SVR: 98% (60/61) | Genotype 6: 98% (60/61) | See Asselah 2019  ENDURANCE-5 |
| Brown 2018144  C-SCAPE (Genotype 4 only)  Multinational (Australia, Belgium, France, Israel, Spain, U.K., U.S.)  *Fair* | A. Elbasvir 50 mg + grazoprevir 100 mg (n=10)  B. Elbasvir 50 mg + grazoprevir 100 mg + ribavirin (n=10) | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post-treatment | A vs. B  SVR: 90% (9/10) vs. 100% (10/10) | NR | NR |
| Chayama 2018197 CERTAIN-1 (Arm A only) Japan  *Fair* | Glecaprevir 300 mg + pibrentasvir 120 mg | Treatment duration: 8 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 99% (128/129) | Genotype 1: 99% (128/129) | NR |
| Chuang 2016145 Taiwan *Fair* | Ledipasvir 90 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 98% (83/85) | Genotype 1: 98% (83/85) | Treatment-naïve: 100% (42/42) Treatment experienced: 95% (41/43) |
| Dore 2016137 MALACHITE-1 Australia, Canada, Europe, South America *Good* | Genotype 1a  A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day + weight-based ribavirin  B. Telaprevir 750 mg 3x/day + subcutaneous pegylated IFN 180 ug 1/week + weight-based ribavirin  Genotype 1b  C. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day + weight-based ribavirin  D. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day  E. Telaprevir 750 mg 3x/day + subcutaneous pegylated IFN 180 ug 1/week + weight-based ribavirin | Treatment duration: 12 weeks; some patients in groups B and D received up to 48 weeks of pegylated IFN / ribavirin  Timing of assessment: 12 weeks post-treatment | Genotype 1a  A vs. B  SVR: 97% (67/69) vs. 82% (28/34)  Genotype 1b  C vs. D vs. E  SVR: 99% (83/84) vs. 98% (81/83) vs. 78% (32/41) | Genotype 1a  A vs. B  SVR: 97% (67/69) vs. 82% (28/34)  Genotype 1b  C vs. D vs. E  SVR: 99% (83/84) vs. 98% (81/83) vs. 78% (32/41) | NR |
| Dore 2016137  MALACHITE-2  Australia, Canada, Europe, South America  *Good* | A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day + weight-based ribavirin  B. Telaprevir 750 mg 3x/day + subcutaneous pegylated IFN 180 ug 1/week + weight-based ribavirin | Treatment duration: 12 weeks; some patients in group B and D received up to 48 weeks of pegylated IFN / ribavirin  Timing of assessment: 12 weeks post-treatment | A vs. B  SVR: 99% (100/101) vs. 66% (31/47) | A vs. B  Genotype 1a: 100% (19/19) vs. 57% (4/7)  Genotype 1b: 99% (81/82) vs. 68% (27/40) | NR |
| Everson 2015 (Part A)146 U.S. *Good* | Part A (trial phase) A. Sofosbuvir 400 mg + velpatasvir 25 mg (Genotype 1) B. Sofosbuvir 400 mg + velpatasvir 100 mg (Genotype 1) C. Sofosbuvir 400 mg + velpatasvir 25 mg (Genotype 3) D. Sofosbuvir 400 mg + velpatasvir 100 mg (Genotype 3) E. Sofosbuvir 400 mg + velpatasvir 25 mg (Genotype 2; 4-6) F. Sofosbuvir 400 mg + velpatasvir 100 mg (Genotype 2; 4-6) | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B vs. C vs. D vs. E vs. F SVR: 96% (26/27) vs. 100% (28/28) vs. 93% (25/27) vs. 93% (25/27) vs. 96% (22/23) vs. 95% (21/22) | A vs. B vs. C vs. D vs. E vs. F Genotype 1, Group A: 96% (26/27)  Genotype 1, Group B: 100% (28/28)  Genotype 3, Group C: 93% (25/27)  Genotype 3, Group D: 93% (25/27)  Genotype 2 or 4-6, Group E: 96% (22/23) Genotype 2 or 4-5, Group F: 95% (21/22) | NR |
| Feld 2014187  SAPPHIRE-1  Australia, New Zealand; Austria, France, Germany, Hungary, Great Britain, Italy, Spain, Sweden, Switzerland; Canada, U.S.  *Good* | A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x day + weight-based ribavirin  B. Placebo for 12 weeks followed by open-label ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x day + weight-based ribavirin | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 96% (455/473) | Genotype  1a: 95% (307/322)  1b: 98% (148/151) | Age <55 years: 97% (95% CI, 94.5 to 98.7); (280/290)  Age ≥55 years: 96% (95% CI, 92.7 to 98.6); (175/183)  Male: 95% (95% CI, 92.7 to 97.8); (258/271)  Female: 98% (95% CI, 95.4 to 99.7); (197/202)  Black: 96% (95% CI, 89.6 to 100.0); (27/28)  Non-Black: 96% (95% CI, 94.4 to 98.0); (428/445)  F0 or F1: 97%( 95% CI, 95.2 to 98.7); (352/363)  F2: 94% (95% CI, 88.9 to 99.7); (66/70)  F3: 93% (95% CI, 84.3 to 100.0); (37/40)  History of diabetes: 100% (95% CI, 100.0-100.0); (19/19)  No history of diabetes: 96% (95% CI, 94.2 to 97.8); (436/454) |
| Feld 2015139 ASTRAL-1 U.S., Canada, Europe, Hong Kong *Good* | A. Sofosbuvir 400 mg + velpatasvir 100 mg  B. Placebo | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B  SVR: 99% (618/624) vs. 0% (0/116) | *Group A only*  Genotype 1: 99% (323/328)  1a: 98% (206/210)  1b: 99% (117/118)  2: 100% (104/104)  4: 100% (116/116)  5: 97% (34/35)  6: 100% (41/41) | *Group A only*  Age <65 years: 99% (530/536)  -Genotype 1: 98% (287/292); Genotype 2: 100% (79/79); Genotype 4: 100% (116/116); Genotype 5: 95% (18/19); Genotype 6: 100% (41/41)  Age ≥65 years: 100% (88/88)  -Genotype 1: 100% (36/36); Genotype 2: 100% (25/25); Genotype 4: 100% (11/11); Genotype 5: 100% (16/16); Genotype 6: 0/0  Male: 99% (369/374)  -Genotype 1: 98% (193/197); Genotype 2: 100% (57/57); Genotype 4: 100% (86/86); Genotype 5: 93% (13/14); Genotype 6: 100% (21/21)  Female: 99.6% (249/250)  -Genotype 1: 99% (130/131); Genotype 2: 100% (47/47); Genotype 4: 100% (30/30); Genotype 5: 100% (21/21); Genotype 6: 100% (21/21)  White: 99% (488/493)  -Genotype 1: 99% (275/279); Genotype 2: 100% (82/82); Genotype 4: 100% (96/96); Genotype 5: 97% (34/35); Genotype 6: 100% (1/1)  Black: 98% (51/52)  -Genotype 1: 96% (24/25); Genotype 2: 100% (13/13); Genotype 4: 100% (14/14); Genotype 5 & 6: 0/0  Other: 100% (76/76)  -Genotype 1: 100% (22/22); Genotype 2: 100% (8/8); Genotype 4: 100% (6/6); Genotype 5 & 6: 0/0  No cirrhosis: 99% (496/501)  -Genotype 1: 98% (251/255); Genotype 2: 100% (93/93); Genotype 4: 100% (89/89); Genotype 5: 97% (28/29); Genotype 6: 100% (35/35)  Cirrhosis: 99% (120/121)  -Genotype 1: 99% (72/73); Genotype 2: 100% (10/10); Genotype 4: 100% (27/27); Genotype 5: 100% (5/5); Genotype 6: 100% (6/6)  Treatment-naïve: 99% (418/423)  -Genotype 1: 98% (214/218; Genotype 1a: 97% [128/132]; Genotype 1b: 100% [86/86]); Genotype 2: 100% (79/79); Genotype 4: 100% (64/64); Genotype 5: 96% (23/24); Genotype 6: 100% (38/38)  Treatment-experienced: 99.5% (200/201)  -Genotype 1: 99% (109/110; Genotype 1a: 100% [78/78]; Genotype 1b: 97% [31/32]); Genotype 2: 100% (25/25); Genotype 4: 100% (52/52); Genotype 5: 100% (11/11); Genotype 6: 100% (3/3) |
| Ferenci 2014188  PEARL III  Austria, Belgium, Hungary, Israel, Italy, Poland, Portugal, Romania, Russia, Spain, U.S.  *Good*  *Same publication as PEARL IV* | A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day  B. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day + ribavirin | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 99% (207/209) vs. 99.5% (209/210) | Genotype 1b: 99% (207/209) vs. 99.5% (209/210) | NR |
| Ferenci 2014188 PEARL IV Canada, U.K., U.S. *Good*  *Same publication as PEARL III* | A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day B. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day + ribavirin | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B SVR: 90% (185/205) vs. 97% (97/100) | Genotype 1a: 90% (185/205) vs. 97% (97/100) | NR |
| Foster 2015147  ASTRAL-2 U.S. *Fair* | A. Sofosbuvir 400 mg + velpatasvir 100 mg B. Sofosbuvir 400 mg + ribavirin | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B SVR: 99% (133/134) vs. 94% (124/132) | Genotype 2: SVR: 99% (133/134) vs. 94% (124/132) | NR |
| Foster 2015147  ASTRAL-3  U.S.  *Fair*  *Same publication as ASTRAL-2* | Same as Foster 2015 ASTRAL-2 | Treatment duration: 12 (group A) or 24 (group B) weeks  Timing of assessment: 12 weeks post-treatment | A vs. B  SVR: 95% (264/277) vs. 80% (221/275) | A vs. B  Genotype 3: 95% (264/277) vs. 80% (221/275) | A vs. B  Age <65 years: 95% (257/270) vs. 81% (210/261)  Age ≥65 years: 100% (7/7) vs. 79% (11/14)  Male: 94% (159/170) vs. 76% (132/175)  Female: 98% (105/107) vs. 88% (89/101)  Black: 100% (3/3) vs. 100% (1/1)  White: 95% (238/250) vs. 78% (187/239)  Other: 96% (23/24) vs. 94% (32/34)  No cirrhosis: 97% (191/197) vs. 87% (163/187)  Cirrhosis: 91% (73/80) vs. 66% (55/83)  Missing data: 0% vs. 60% (3/5)  Treatment-naive: 97% (200/206) vs. 86% (176/204)  Treatment-experienced: 90% (64/71) vs. 63% (45/71)  No cirrhosis + treatment-naive: 98% (160/163) vs. 90% (141/156)  No cirrhosis + treatment-experienced: 91% (31/34) vs. 71% (22/31) |
| Gane 2015148 New Zealand (Genotype 6 subset) *Fair* | Ledipasvir 90 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 96% (24/25) | Genotype 6: 96% (24/25) | NR |
| Grebely 2018a150  SIMPLIFY  Multinational (Australia, Canada, New Zealand, Norway, Switzerland, U.K., U.S.)  *Fair* | Sofosbuvir 400 mg + velpatasvir 100 mg | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 94% (97/103) | NR | Male: 92% (68/74)  Female: 100% (29/29)  Age ≤41 years: 93% (26/28)  Age >41 years: 95% (71/75)  F0 and F1: 97% (57/59)  F2 and F3: 93% (25/27)  Cirrhosis: 78% (7/9)  Current opioid substitution therapy: 96% (43/45)  No current opioid substitution therapy: 93% (54/58)  Recent IVDU: 95% (72/76)  No recent IVDU: 93% (25/27) |
| Grebely 2018b149 D3FEAT Multinational (Australia, Canada, France, New Zealand, Norway, Switzerland)  *Fair* | Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg + 1000 to 1200 mg ribavirin | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 91% (79/87) | Genotype 1: 91% (79/87) | Male: 91% (61/67) Female: 90% (18/20) Age ≤54 years: 89% (59/66) Age >54 years: 95% (20/21) F0 and F1: 90% (61/68) F2 and F3: 100% (12/12) Cirrhosis: 86% (6/7) Recent IVDU: 93% (39/42) No recent IVDU: 89% (40/45) |
| Hezode 2015189 PEARL I (Treatment-naïve population) France, Hungary, Italy, Poland, Romania, Spain, Turkey, U.S. *Good*  *See also Lawitz 2015155 (PEARL I - Genotype 1b)* | Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + ribavirin (weight-based; dose NR) | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 100% (42/42) | Genotype 4: 100% (42/42) | NR |
| Hezode 2015189  PEARL I (Treatment experienced population)  France, Hungary, Italy, Poland, Romania, Spain, Turkey, U.S.  *Good*  *See also Lawitz 2015155 (PEARL I - Genotype 1b)* | Same as Hezode 2015 (Treatment naïve population) | Same as Hezode 2015 (Treatment naïve population) | SVR: 100% (49/49) | Genotype 4: 100% (49/49) | NR |
| Kowdley 2014a190  ION-3  U.S.  *Fair* | Ledipasvir 90 mg + sofosbuvir 400 mg | Treatment duration: 8 to 12 weeks  Timing of assessment: 12 weeks post-treatment | 8-week intervention group  SVR: 94% (202/215)  12-week intervention group  SVR: 95% (206/216) | 8-week intervention group  Genotype 1a: 93% (159/171)  Genotype 1b: 98% (42/43)  Unconfirmed subtype: 100% (1/1)  12-week intervention group  Genotype 1a: 95% (163/172)  Genotype 1b: 98% (43/44) | 8-week intervention group  <65 years: 94% (185/196)  ≥65 years: 90% (17/19)  Male: 92% (119/130)  Female: 98% (83/85)  Black: 91% (41/45)  Non-black: 95% (161/170)  Hispanic: 100% (13/13)  Non-Hispanic: 94% (187/200)  12-week intervention group  <65 years: 95% (189/199)  ≥65 years: 100% (17/17)  Male: 95% (122/128)  Female: 96% (84/85)  Black: 95% (40/42)  Non-black: 95% (165/173)  Hispanic: 93% (13/14)  Non-Hispanic: 96% (193/202) |
| Kowdley 2014b191 AVIATOR Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, U.K., U.S. *Good* | A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 150 mg + dasabuvir 800 mg  B. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100-150 mg + dasabuvir 800 mg + ribavirin 1000-1200 mg | Treatment duration:  12 weeks   Timing of assessment: 24 weeks post-treatment | A vs. B SVR, 12 weeks post-treatment: 91% (72/79) vs. 99% (78/79) SVR, 24 weeks post-treatment: 89% (70/79) vs. 96% (76/79) | A vs. B Genotype 1a + treatment naive: 83% (43/52) vs. 94% (51/54) Genotype 1b + treatment naive: 100% (25/25) vs. 100% (25/25) | A vs. B Black: 100% (13/13) vs. 100% (13/13) Non-black: 86% (57/66) vs. 96% (63/66) |
| Kumada 2017 (Part 2 only)152 Japan *Good* | Elbasvir 50 mg + grazoprevir 100 mg | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 97% (219/227) | Genotype 1a: 100% (4/4)  Genotype 1b: 96% (215/223) | <65 years: 99% (122/123)  65-74 years: 93% (70/75)  ≥75 years: 93% (27/29)  Male: 98% (85/87)  Female: 96% (134/140)  Treatment-naïve: 97% (144/149)  Treatment-experienced: 96% (75/78) |
| Kumada 2015151  GIFT-1 (Substudy 1)  Japan  *Fair* | A. Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg (double-blind treatment) B. Placebo for 12 weeks, followed by ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg (open-label treatment) | Treatment duration:  12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B SVR: 95% (204/215) vs. 98% (104/106) | A vs. B Genotype 1b: 95% (204/215) vs. 98% (104/106) | A vs. B Treatment-naïve: 94.2% (131/139) vs. 98/5% (67/68) Treatment-experienced: 96.1% (73/76) vs. 97.4% (37/38) |
| Kwo 2016153 OPTIMIST-1 Canada, U.S. *Fair* | Simeprevir 150 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks Timing of assessment: 12 weeks post-treatment | SVR: 97% (150/155) | Genotype 1a: 97% (112/116) Genotype 1b: 97% (38/39) | Treatment-naïve: 97% (112/115) Treatment experienced: 95% (38/40) |
| Lalezari 2015192  U.S.  *Fair* | Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + dasabuvir 250 mg 2x/day + ribavirin 1000-1200 mg | Treatment duration: 12 weeks Timing of assessment: 12 and 24 weeks post treatment | SVR, 12 weeks: 97.4% (37/38) SVR, 24 weeks: 97.4% (37/38) | Genotype 1, 12 weeks: 97.4% (37/38) Genotype 1, 24 weeks: 97.4% (37/38) | NR |
| Lawitz 2014a154 COSMOS  U.S. *Fair* | A. Simeprevir 150 mg + sofosbuvir 400 mg  B. Simeprevir 150 mg + sofosbuvir 400 mg + ribavirin | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post treatment | SVR: 92.9% (13/14) vs. 96% (26/27) | Genotype 1: 92.9% (13/14) vs. 96% (26/27) | Treatment-naïve: (4/4) vs. (5/6) |
| Lawitz 2014b193 LONESTAR (Cohort A) U.S. *Fair* | A. Ledipasvir 90 mg + sofosbuvir 400 mg, 8 weeks B. Ledipasvir 90 mg + sofosbuvir 400 mg, 12 weeks C. Ledipasvir 90 mg + sofosbuvir 400 mg + ribavirin | Treatment duration: 8 and 12 weeks  Timing of assessment: 12 weeks post treatment | A vs. C 8-week intervention group SVR: 95% (19/20) vs. 100% (21/21)  B 12-week intervention group SVR: 95% (18/19) | A vs. C 8-week intervention group Genotype 1: 95% (19/20) vs. 100% (21/21)  B 12-week intervention group Genotype 1: 95% (18/19) | NR |
| Lawitz 2015155  PEARL-1  France, Hungary, Italy, Poland, Puerto Rico, Romania, Spain, Turkey, U.S.  *Fair* | Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 92.7% (76/82) | Genotype 1b: 92.7% (76/82) | Treatment-naïve: 95.2% (40/42) Treatment-experienced: 90.0% (36/40) |
| Lim 2016156 Korea *Fair* | Ledipasvir 90 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post treatment | SVR: 100% (46/46) | Genotype 1: 100% (46/46) | Age <65 years: 100% (33/33) Age ≥65 years: 10% (13/13) |
| Nelson 2015157 ALLY-3 U.S. *Fair* | Daclatasvir 60 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | SVR: 90% (91/101) | Genotype 3: 90% (91/101) | Age <65 years: 90% (128/142)†  Age ≥65 years: 70% (7/10)†  Male gender: 86% (77/90)†  Female gender: 94% (58/62)†  F0-F3: 95% (72/76)  F4: 73% (16/22)  Treatment-naïve: 97% (73/75)  Treatment-experienced: 94% (32/34) |
| Pianko 2015158 Australia, New Zealand, U.S. *Fair* | A. Sofosbuvir 400 mg + velpatasvir 100 mg (Group 3) B. Sofosbuvir 400 mg + velpatasvir 100 mg + ribavirin (Group 4) | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B SVR: 100% (27/27) vs. 100% (26/26) | A vs. B Genotype 3: 100% (27/27) vs. 100% (26/26) | NR |
| Poordad 2017194  MAGELLAN-1  U.S.  *Fair* | A. Glecapravir 200 mg + pibrentasvir 80 mg B. Glecapravir 200 mg + pibrentasvir 120 mg C. Glecapravir 200 mg + pibrentasvir 120 mg + ribavirin | Treatment duration: 12 weeks Timing of assessment: 12 weeks post-treatment | A vs. B vs. C SVR: 100% (6/6) vs. 86% (19/22) vs. 95% (21/22) | A vs. B vs. C Genotype 1: 100% (6/6) vs. 86% (19/22) vs. 95% (21/22) | NR |
| Pott-Junior 2019 (Group A - daclatasvir/ sofosbuvir arm)159 Brazil  *Good* | Daclatasvir 60 mg + sofosbuvir 400 mg | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 100% (65/65) | Genotype 1a: 100% (27/27)  Genotype 1b: 100% (35/35) | Treatment-naïve: 100% (39/39)  Treatment-experienced: 100% (26/26) |
| Pott-Junior 2019 (Group B - simeprevir/ sofosbuvir arm)159 Brazil  *Good* | Simeprevir 150 mg + sofosbuvir 400 mg | See Pott-Junior 2019 Group A | SVR: 93% (56/60) | Genotype 1a: 90% (28/31) Genotype 1b: 96% (27/28) | Treatment-naïve: 97% (35/36) Treatment-experienced: 88% (21/24) |
| Sperl 2016198 and Ng 2018138 C-EDGE Head-2-Head (elbasvir/grazoprevir arm only) Multinational (Europe, Turkey)  *Fair* | Elbasvir 50 mg + grazoprevir 100 mg | Treatment duration: 12 weeks Timing of assessments: 12 weeks post-treatment | SVR: 99% (128/129) | Genotype 1a: 100% (18/18) Genotype 1b: 99% (104/105) Genotype 4: 100% (6/6) | Male: 100% (55/55) Female: 99% (73/74) Age ≤40 years: 100% (37/37) Age 41 to 50 years: 100% (31/31) Age 51 to 60 years: 98% (40/41) Age 61 to 70 years: 100% (20/20) No cirrhosis: 99% (106/107) Cirrhosis: 100% (22/22) Treatment-naive: 99% (99/100) Treatment-experienced: 100% (29/29) |
| Sulkowski 2014161  A1444040 Study  U.S.  *Fair* | A. Sofosbuvir 400 mg + daclatasvir 60 mg B. Sofosbuvir 400 mg + daclatasvir 60 mg + ribavirin | Treatment duration: 12 weeks Timing of assessment: 12 weeks post-treatment | A vs. B SVR: 100% (41/41) vs. 95% (39/41) | NR | NR |
| Sulkowski 2015160 C-WORTHY Australia, Canada, Denmark France, Hungary, Israel, New Zealand, Puerto Rico, Spain, Sweden, Turkey, U.S. *Fair* | A. Grazoprevir 100 mg + elbasvir 50 mg  B. Grazoprevir 100 mg + elbasvir 50 mg + ribavirin | Treatment duration: 12 weeks  Timing of assessment: 12 weeks post-treatment | A vs. B  SVR: 98% (43/44) vs. 93% (79/85) | A vs. B  Genotype 1: 98% (43/44) vs. 93% (79/85) | NR |
| Toyoda 2018199 CERTAIN-2 (Arm A only) Japan  *Fair* | Glecaprevir 300 mg + pibrentasvir 120 mg | Treatment duration: 8 weeks Timing of assessments: 12 weeks post-treatment | SVR: 98% (88/90) | Genotype 2: 98% (88/90) | NR |
| Waked 2016162 AGATE-II Egypt *Good* | Ombitasvir 25 mg + paritaprevir 150 mg + ritonavir 100 mg + 1000 to 1200 mg ribavirin | Treatment duration: 12 weeks Timing of assessment: 12 weeks post-treatment | SVR: 94% (94/100) | Genotype 4: 94% (94/100) | NR |
| Wei 2018163  China  *Fair* | Ledipasvir 90 mg + sofosbuvir 400 mg + | Treatment duration: 12 weeks Timing of assessments: 12 weeks post-treatment | SVR: 100% (206/206) | Genotype 1: 100% (206/206) | Treatment-naïve: 100% (106/106) Treatment-experienced: 100% (100/100) |
| Wei 2019a164 C-CORAL (Genotype 1 and 4 only) Multinational (Australia, China, Korea, Russia, Taiwan, Thailand, Vietnam)  *Good* | A. Elbasvir 50 mg + grazoprevir 100 mg (n=326)  B. Placebo (n=123; harms assessment only) | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post-treatment | SVR-12: 94% (459/486)  SVR-24: 94% (458/486) | SVR-12  Genotype 1a: 92% (34/37)  Genotype 1b: 98% (382/389)  Genotype 1-other: 100% (6/6)  Genotype 4: 100% (3/3)  SVR-24 Genotype 1a: 92% (34/37) Genotype 1b: 98% (381/389) Genotype 1-other: 100% (6/6) Genotype 4: 100% (3/3) | SVR-12  Male: 96% (207/216)  Female: 93% (252/270)  Asian: 93% (325/350)  White: 99% (133/135)  Other: 1005 (1/1)  Hispanic/Latino: 100% (5/5)  Non-Hispanic/Latino: 94% (454/481)  Age <65 years: 95% (420/444)  Age ≥65 years: 93% (39/42)  No cirrhosis: 95% (375/396)  Cirrhosis: 93% (84/90)  SVR-24 Male: 95% (206/216) Female: 93% (252/270) Asian: 93% (324/350) White: 99% (133/135) Other: 1005 (1/1) Hispanic/Latino: 100% (5/5) Non-Hispanic/Latino: 94% (453/481) Age <65 years: 95% (420/444) Age ≥65 years: 91% (38/42) No cirrhosis: 95% (375/396) Cirrhosis: 93% (84/90) |
| Wei 2019b165 Multinational (China, Malaysia, Singapore, Thailand, Vietnam)  *Fair* | Sofosbuvir 400 mg + velpatasvir 100 mg | Treatment duration: 12 weeks  Timing of assessments: 12 weeks post-treatment | SVR: 97% (362/375) | Genotype 1a: 100% (22/22)  Genotype 1b: 100% (107/107)  Genotype 2: 100% (64/64)  Genotype 3a and unconfirmed subtype: 95% (40/42)  Genotype 3b: 76% (32/42)  Genotype 6: 99% (97/98) | Male: 94% (186/197)  Female: 99% (176/178)  Age <65 years: 96% (340/353)  Age ≥65 years: 100% (22/22)  No cirrhosis: 98% (302/308)  Cirrhosis: 90% (60/67)  Treatment-naive: 97% (297/307)  Treatment-experienced: 96% (65/68) |
| Zeuzem 2015166 C-EDGE Multinational (Australia, Czech Republic, France, Germany, Israel, Puerto Rico, South Korea, Taiwan, U.S.) *Good* | Grazoprevir 100 mg + elbasvir 50 mg | Treatment duration: 12 weeks Timing of assessments: 14 weeks post treatment | *Patients without cirrhosis only* SVR: 94% (231/246) | Genotype 1a: 92% (144/157) Genotype 1b: 98% (129/131) Genotype 4: 100% (18/18) | NR |
| Zeuzem 2018167  ENDURANCE-1  Multinational (Australia, Austria, Belgium, Canada, Chile, France, Germany, Hungary, Israel, Italy, Lithuania, Mexico, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, South Korea, Sweden, Switzerland, Taiwan, U.K., U.S.)  *Fair* | Glecaprevir 300 mg + pibrentasvir 120 mg | Treatment duration: 8 weeks  Timing of assessments: 12 and 24 weeks post-treatment | 8-week intervention group  SVR-12 (includes n=15 with HIV coinfection and n=1 with prior sofosbuvir treatment): 99% (348/351)  SVR-12 (excluding HIV positive patients and those with prior sofosbuvir treatment): 99% (332/335)  SVR-24: 98% (343/351)  12-week intervention group  SVR-12 (includes n=18 with HIV co-infection and n=2 with prior sofosbuvir treatment): 99.7% (351/352)  SVR-12 (excluding HIV positive patients and those with prior sofosbuvir treatment): 99.7% (331/332)  SVR-24: 98% (345/352) | 8-week intervention group  Genotype 1a: 98% (150/153)  Other genotype 1: 100% (198/198)  12-week intervention group  Genotype 1a: 99% (148/149)Other genotype 1: 100% (203/203) | 8-week intervention group  Male: 99% (165/167)  Female: 99% (183/184)  Black race: 100% (14/14)  Other race: 99% (334/337)  Age <65 years: 99% (306/309)  Age ≥65 years: 100% (42/42)  Treatment-naive: 99% (217/219)  Treatment-experienced: 99% (131/132)  People who inject drugs (recent or history): 98% (96/98)  Not people who inject drugs: 99.6% (252/253)  No current opioid substitution therapy: 99% (336/339)  Current opioid substitution therapy: 100% (12/12)  12-week intervention group  Male: 100% (176/176)  Female: 99% (175/176)  Black race: 92% (12/13)  Other race: 100% (339/339)  Age <65 years: 99.7% (316/317)  Age ≥65 years: 100% (35/35)  Treatment-naive: 99.5% (216/217)  Treatment-experienced: 100% (135/135)  People who inject drugs (recent or history): 100% (97/97)  Not people who inject drugs: 99.7% (254/255)  No current opioid substitution therapy: 100% (336/336)  Current opioid substitution therapy: 94% (15/16) |
| Zeuzem 2018167 ENDURANCE-3 (same publication as ENDURANCE-1)  *Fair* | A. Glecaprevir 300 mg + pibrentasvir 120 mg, 8 weeks B. Glecaprevir 300 mg + pibrentasvir 120 mg, 12 weeks 3. Sofosbuvir 400 mg + daclatasvir 60 mg. 12 weeks | Treatment duration: 8 to 12 weeks  Timing of assessments: 12 and 24 weeks post-treatment | A vs. B vs. C SVR-12: 95% (149/157) vs. 95% (222/233) vs. 97% (111/115) SVR-24: 91% (143/157) vs. 92% (214/233) vs. 96% (110/115) | Genotype 3a: 95% (148/156) vs. 96% (220/230) vs. 97% (111/115)  Other genotype 3: 100% (1/1) vs. 67% (2/3) vs. NA | Male: 93% (86/92) vs. 93% (112/121) vs. 92% (48/52) Female: 97% (63/65) vs. 98% (110/112) vs. 100% (63/63)  Black race: 100% (3/3) vs. 100% (4/4) vs. 75% (3/4) Not Black race: 95% (146/154) vs. (218/229) vs. 97% (108/111)  Age <65 years: 95% (144/152) vs. 95% (213/224) vs. 96% (107/111) Age ≥65 years: 100% (5/5) vs. 100% (9/9) vs. 100% (4/4)  People who inject drugs (recent or history): 94% (98/104) vs. 93% (139/149) vs. 96% (70/73) Not people who inject drugs: 96% (51/53) vs. 99% (83/84) vs. 98% (41/42)  No current opioid substitution therapy: 94% (119/126) vs. 96% (188/195) vs. 96% (94/98) Current opioid substitution therapy: 97% (30/31) vs. 90% (34/38) vs. 100% (17/17) |

\*Excluding patients who withdrew or were lost to follow up.

†Based on total study population (treatment naïve and experienced combined).

**Abbreviations:** IFN = interferon; IVDU = injection drug use; NR = not reported; SVR = sustained virologic response; U.K. = United Kingdom; U.S. = United States. Study names are not acronyms.